¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bone Density Conservation Agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • cranial bone
    ¸Ó¸®»À, µÎ°³°ñ
  • cranial bone flap
    ¸Ó¸®»ÀÇÇÆÇ(¼ú), µÎ°³°ñÇÇÆÇ
  • cuboid bone
    ÀÔ¹æ»À
  • cuneiform bone
    ½û±â»À, ¼³»ó°ñ
  • carpal bone
    ¼Õ¸ñ»À, ¼ö±Ù°ñ
  • cartilage bone
    ¿¬°ñ»À
  • cancellous bone
    °¹¼Ø»À, ÇØ¸é°ñ
  • endochondral bone
    ¿¬°ñ³»»À
  • ethmoid bone
    ¹úÁý»À, »ç°ñ
  • fibrous dysplasia of bone
    »À¼¶À¯Çü¼ºÀÌ»ó
  • flat bone
    ³³ÀÛ»À, ÆíÆò°ñ
  • frontal bone
    À̸¶»À, ÀüµÎ°ñ
  • heel bone
    ¹ß²ÞÄ¡»À, Á¾°ñ
  • herring bone appearance
    û¾î»À¸ð¾ç
  • herring bone artifact
    û¾î»ÀÇã»ó, û¾î»ÀÀΰø¹°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • brittle bone
    (¢¡osteogenesis imperfecta) ºÒ¿ÏÀü»À¹ß»ý, ºÒ¿ÏÀü°ñÇü¼ºÁõ
  • cancellous bone
    (¢¡spongy bone) °¹¼Ø»À, ÇØ¸é»À
  • capitate bone
    ¾Ë¸Ó¸®»À
  • carpal bone
    ¼Õ¸ñ»À
  • cartilage bone
    ¿¬°ñ»À
  • collar bone
    (¢¡clavicle) ºøÀå»À, ¼â°ñ
  • compact bone
    Ä¡¹Ð»À
  • cortical bone
    °ÑÁú»À
  • costal bone
    (¢¡rib) °¥ºñ»À, ´Á°ñ
  • cranial bone
    ¸Ó¸®»À, µÎ°³°ñ
  • cuboid bone
    ÀÔ¹æ»À
  • cuneiform bone
    ½û±â»À
  • ethmoid bone
    ¹úÁý»À, »ç°ñ
  • flat bone
    ³³ÀÛ»À
  • frontal bone
    À̸¶»À
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • quadrate bone
    ¹æ°ñ(Û°Íé), ¹æÇü°ñ.
  • reactive bone excrescence
    ¹ÝÀÀ¼º °ñ µ¹Ãâ
  • red bone marrow
    Àû»ö°ñ¼ö(îåßäÍéâÐ).
  • red bone marrow
    Àû»ö°ñ¼ö (Àû»ö»À¼ÓÁú)
  • red bone marrow
    Àû»ö°ñ¼ö(îåßäÍéâÐ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • spin density weighted image
    ½ºÇÉ ¹Ðµµ °­Á¶ ¿µ»ó
  • vapo density
    Áõ±â¹Ðµµ.
  • very low density lipoprotein
    ±ØÀúºñÁßÁö´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁö´Ü¹é(Áú)
  • very low density lipoprotein =VLDL
    ÃÊÀúºñÁßÁö(Áú)´Ü¹é(Áú).
  • very low-density lipoprotein =VLDL
    ÃÊÀú¹ÐµµÁö(Áú)´Ü¹é(Áú).
  • accessory bone =extra ossicle
    Á¾ÀÚ°ñ(ðúí­Íé), ºÎ°ñ(ÜùÍé), À׿©°ñ(í¥æ®Íé).
  • air bone gap =AB g.
    ±âµµ°ñµµ(û·Â)Â÷
  • alveolar bone
    ÀÌÆ²»À
  • articular surface for cuboid bone
    ÀÔ¹æ°üÀý¸é
  • articular surface for navicular bone
    ¹ß¹è°üÀý¸é
  • aseptic bone necrosis
    ¹«±Õ¼º °ñ ±«»ç(ÙíжàõÍéÎÕÞÝ).
  • astragaloscaphoid bone
    °Å°ñ ÁÖ»ó°ñ(¡­ñÇßÒÍé).
  • audiometry, bone conduction
    °ñµµÃ»·Â û°¢°Ë»ç
  • autogenous bone graft
    ÀÚ°¡°ñ À̽Ä(¼ú)(í»Ê«Íéì¹ãÖâú).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Body of hyoid bone
    ¸ñ»Ô»À¸öÅë
    [¿¾ ¿ë¾î] ¼³°ñü
  • Inferior body of hyoid bone
    ¸ñ»Ô»À¾Æ·¡¸öÅë
    [¿¾ ¿ë¾î] ¼³°ñÇÏü
  • Superior body of hyoid bone
    ¸ñ»Ô»ÀÀ§¸öÅë
    [¿¾ ¿ë¾î] ¼³°ñ»óü
  • Hip bone
    º¼±â»À [°ü°ñ]
    [¿¾ ¿ë¾î] °ü°ñ
  • Bone tissue
    »ÀÁ¶Á÷
    [¿¾ ¿ë¾î] °ñÁ¶Á÷
  • Histogenesis of bone
    »ÀÁ¶Á÷¹ß»ý
    [¿¾ ¿ë¾î] °ñ¹ß»ý
  • Reticulofibrous bone tissue
    ¼¼¸Á¼¶À¯»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ¼¼¸Á¼¶À¯¼º°ñÁ¶Á÷
  • Cuboid bone
    ÀÔ¹æ»À
    [¿¾ ¿ë¾î] ÀÔ¹æ°ñ
  • Tuberosity of cuboid bone
    ÀÔ¹æ»À°ÅÄ£¸é
    [¿¾ ¿ë¾î] ÀÔ¹æ°ñÁ¶¸é
  • Pisiform bone
    Äá¾Ë»À
    [¿¾ ¿ë¾î] µÎ»ó°ñ
  • Long bone
    ±ä»À
    [¿¾ ¿ë¾î] Àå°ñ
  • Short bone
    ªÀº»À
    [¿¾ ¿ë¾î] ´Ü°ñ
  • Sponge bone
    ÇØ¸é»À
    [¿¾ ¿ë¾î] ÇØ¸é°ñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
ABMI autologous bone marrow transplantation
ABMT American Board of Medical Toxicology; autologous bone marrow transplantation
AC/BC air conduction/bone conduction [time ratio]
ADR activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ...
ANB avascular necrosis of bone
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
LDL E/low density lipoprotein
ECD Endothelial cell density
FD Fiber density
FCD Functional capillary density
HELP Heparin-induced extracorporeal low density lipoprotein precipitation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bone substance
    °ñÁú
  • bone swedging
    °ñ ¾ÐÀÎ
  • bone tissue
    »À Á¶Á÷, °ñ Á¶Á÷
  • bone tuberculosis
    °ñ °áÇÙ
    »À¿¡ ¹ß»ýÇÏ´Â °áÇÙÁõ. ÁÖ·Î Æó °áÇÙ¿¡¼­ 2Â÷ °¨¿°¿¡ ÀÇÇØ Ç÷Ç༺À¸·Î ¹ß»ýÇϰųª, ±ÙÁ¢ Àå±â·ÎºÎÅÍ ¿¬¼ÓÀûÀ¸·Î ħ¹üµÇ¾î ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹°í, ¿ø¹ß¼ºÀÎ °ÍÀº µå¹°´Ù. °¡Àå ¸¹ÀÌ ¹ß»ýÇÏ´Â ºÎÀ§´Â Àå°ü »ó°ñÀÇ ´ÜºÎ¿Í Áß°£ºÎÀ̸ç û³â ¹× Àå³âÃþ¿¡ ¸¹´Ù. °ñ¼ö°¡ ħ¹üµÇ¸é °ñ¼ö ¼Ó¿¡ °áÇÙ º´¼Ò¸¦ Çü¼ºÇÏ¿© ÁÖÀ§ÀÇ °ñ Á¶Á÷À» ÆÄ±«ÇÏ°í ¸¶Ä§³»´Â ÇѼº ³ó¾çÀ» ÀÏÀ¸Å²´Ù. °ñ¸·ÀÌ Ä§¹üµÇ¸é °ñ¸éÀ» ħ½ÄÇÏ¿© Ä«¸®¿¡½º
  • bone tumor
    °ñ Á¾¾ç
    óÀ½¿¡ »À¿¡ ¹ß»ýÇÏ´Â Á¾¾ç. ´Ù¸¥ ºÎÀ§¿¡¼­ ¾ÏÀÌ ÀüÀÌÇÏ´Â Àϵµ ÀÖÀ¸³ª, ´ëºÎºÐÀº Á¶°ñ¼¼Æ÷³ª Á¶Á÷ÀÇ ÀÌ»ó Áõ½Ä¿¡ ÀÇÇÏ¿© »ý±ä´Ù. °ñ Á¶Á÷ ÀÚü¿¡¼­ ¹ß»ýÇÏ´Â Á¾¾çÀ¸·Î´Â °ñÁ¾, ¿¬°ñÁ¾ÀÌ ÀÖ°í, »À¿¡ Æ÷ÇÔµÈ °áÇÕÁ¶Á÷¿¡¼­ ¹ß»ýÇÏ´Â ¼¶À¯Á¾, Ç÷°ü¿¡¼­ ¹ß»ýÇÏ´Â Ç÷°üÁ¾, °ñ¼ö¿¡¼­ ¹ß»ýÇÏ´Â °ñ¼öÁ¾ÀÌ ÀÖ´Ù. °ñ¼öÁ¾À» Á¦¿ÜÇϰí´Â ¸ðµÎ ¾ç¼º Á¾¾çÀ¸·Î »ý¸íÀÇ À§ÇèÀÌ µû¸£´Â ÀÏÀº ¾ø°í °ÅÀÇ Å¸°¢ ¼Ò°ß
  • bone turnover
    °ñ ±³Ã¼
  • bone-marrow blood transfusion
    °ñ¼ö ¼öÇ÷
    °æ°ñ°ú Èä°ñÀÇ °ñ¼ö¿¡ Ç÷¾×À» ÁÖÀÔÇÏ´Â ¼öÇ÷ÀÇ º¯¹ý. Ç×»ó ¾²´Â Á¤¸Æ ³» ¼öÇ÷·Î´Â °¨¼ö¼ºÀÌ Áö³ªÄ¡°Ô °­Çϰųª ¸öÀÌ ºñ¸¸ÇÏ¿© Á¤¸ÆÀ» ã±â ¾î·Á¿î ȯÀÚ ¶Ç´Â À¯¾Æ¸¦ ´ë»óÀ¸·Î ÇÒ °æ¿ì ÀÌ ¹æ¹ýÀ¸·Î ¼öÇ÷ÇÒ ¶§°¡ ÀÖ´Ù. ¶Ç ¹éÇ÷º´À̳ª Àç»ýºÒ·®¼º ºóÇ÷ ȯÀÚ¿¡°Ô´Â ÀÌ ¹æ¹ýÀÌ Á¤¸Æ ¼öÇ÷º¸´Ù ¶Ù¾î³­ È¿°ú°¡ ÀÖ´Ù´Â °ßÇØµµ ÀÖ´Ù. ¹æ¹ýÀº °ñ¼ö õÀÚ¸¦ ÇÏ¿© Á¡Àû ÀåÄ¡ ¶Ç´Â ´ëÇü ÁÖ»ç±â·Î äÇ÷ÇÑ Ç÷¾×À» °ñ¼ö ³»¿¡ ÁÖÀÔÇÑ´Ù. ´Ù·® ¼öÇ÷ÀÌ °¡´ÉÇÏÁö¸¸, ±¹ºÎ ÇÇºÎ¿Í °ñ¸·¿¡ ±¹¼Ò¸¶Ã븦 ÇØ¾ß ÇÒ Çʿ䰡 ÀÖ´Ù. ±×¸®°í Á¤¸Æ ¼öÇ÷º¸´Ù ½Ã°£ÀÌ °É¸®°í ¼¼½ÉÇÑ ÁÖÀǰ¡ ÇÊ¿äÇϸç, ȯÀÚ¿¡°Ô °íÅëÀ» Áְųª, ³Ê¹« »¡¸® ÁÖÀÔÇÏ¸é ±¹¼Ò¿¡ ÅëÁõÀ» ÁÖ´Â µîÀÇ °áÁ¡ÀÌ ÀÖ´Ù.
  • bone-salt
    °ñ¿°
    °ñ³»ÀÇ ÁÖ¿ä È­ÇÕ¹°·Î¼­ ±³¿øÁúÀ» ÇÔÀ¯ÇÑ ±³¿ø¼¶À¯ÀÇ °ñ ±âÁú³»¿¡ ÀÛÀº °áÁ¤À¸·Î¼­ Ä§ÂøµÇ¾î ÀÖ´Ù. ÀÚ¿¬°è¿¡ Á¸ÀçÇÏ´Â ºÒ¼Ò ÀÎȸ¼®°ú À¯»çÇϳª, °ñ¿°Àº F°¡ OH·Î ġȯµÈ ¼ö»êÀÎȸ¼®À̶ó°í »ý°¢µÈ´Ù.
  • brush bone
    ¼âÀÚ¿¬
    ¼¼Æ÷ Ç¥¸éÀÌ ºÐÈ­µÈ °ÍÀ¸·Î¼­, Ç¥¸éÀûÀ» Å©°Ô Áõ´ë½ÃŰ´Â ¹Ì¼¼ÇÑ ¿øÅë»ó µ¹±â·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ƯÈ÷ ôÃßµ¿¹° ¼¼´¢°üÀÇ ±ÙÀ§ ±¼°îºÎ »óÇǼ¼Æ÷³ª Àå°ü »óÇǼ¼Æ÷¿¡¼­ Àß ¹ß´ÞµÇ¾î ÀÖ´Ù.
  • bundle bone
    ¼Ó»ó°ñ
    Shar
  • calf's bone
    ºñ°ñ
    µ¿ÀǾî=fibula. ÇÏÅðÀÇ µÎ °³ÀÇ »À Áß¿¡¼­ ¹Ù±ùÂÊÀÇ ÀÛÀº °Í.
  • carpal bone
    ¼Õ¸ñ»À, ¼ö±Ù°ñ
  • cartilagenous bone
    ¿¬°ñ »À
    Ư¼öÇÑ ¼¶À¯¼º °áÇÕÁ¶Á÷ÀÇ »À. žÆÀÇ ÀϽÃÀû °ñ°ÝÀ» Çü¼ºÇÏ °í, °ñÀÌ ¹ß´ÞÇϱâ À§ÇÑ ÇüÀ» Á¦°øÇϸç, »ý¹° ¼ºÀå±â±¸ÀÇ Áß¿ä ºÎºÐÀ» ±¸¼ºÇÑ´Ù.
  • cartilaginous bone
    ¿¬°ñ¼º °ñ
  • cheek bone
    °ü°ñ
    µ¿ÀǾî=zygoma.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
gaba agents Substances used for their pharmacological actions on gabaergic systems. Gabaergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function.
(12 Dec 1998)
radiation-protective agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other, e.g. Military, purposes.
(12 Dec 1998)
radiation-sensitizing agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
(12 Dec 1998)
vasoconstrictor agents Drugs used to cause constriction of the blood vessels.
(12 Dec 1998)
vasodilator agents Drugs used to cause dilation of the blood vessels.
(12 Dec 1998)
gastrointestinal agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
(12 Dec 1998)
reducing agents Materials that add an electron to an element or compound, that is, decrease the positiveness of its valence.
(12 Dec 1998)
renal agents Drugs used for their effects on the kidneys' regulation of body fluid composition and volume. The most commonly used are the diuretics. Also included are drugs used for their antidiuretic and uricosuric actions, for their effects on the kidneys' clearance of other drugs, and for diagnosis of renal function.
(12 Dec 1998)
reproductive control agents Substances used either in the prevention or facilitation of pregnancy.
(12 Dec 1998)
central nervous system agents A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "non-specific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with non-specific mechanisms are generally further classed according to whether they produce behavioural depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use.
(12 Dec 1998)
glycine agents Substances used for their pharmacological actions on glycinergic systems. Glycinergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function.
(12 Dec 1998)
respiratory system agents Drugs used for their effects on the respiratory system.
(12 Dec 1998)
menstruation-inducing agents Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhoea is a secondary result.
(12 Dec 1998)
chelating agents Organic chemicals that form two or more coordination bonds with a central metal ion. Heterocyclic rings are formed with the central metal atom as part of the ring. Some biological systems form metal chelates, e.g., the iron-binding porphyrin group of haemoglobin and the magnesium-binding chlorophyll of plants. They are used chemically to remove ions from solutions, medicinally against microorganisms, to treat metal poisoning, and in chemotherapy protocols.
(12 Dec 1998)
chemical warfare agents Chemicals that are used to cause the disturbance, disease, or death of humans during war.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á